For a person wanting to be a doctor, my...

It’s very common for a pharma professional having neighbors, friends and relatives to engage in conversation over medicines. One such conversation – a pleasant surprise – which intrigued me to dig deep into internet dynamics was one with the local roadside Sabziwali.

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).

The Beginning I was at crossroads after completing computer...

Key Point from the Q &A with Dr. Mandar...

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

A quiet but revolutionary milestone may be unfolding in...

India’s pharmaceutical industry runs on the strength of its...

The Delhi High Court has restrained Dr. Reddy’s and...

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

A quiet but revolutionary milestone may be unfolding in...

India’s pharmaceutical industry runs on the strength of its...

The Delhi High Court has restrained Dr. Reddy’s and...

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

A quiet but revolutionary milestone may be unfolding in...

India’s pharmaceutical industry runs on the strength of its...

The Delhi High Court has restrained Dr. Reddy’s and...

Key Insights Thermo Fisher Scientific leads the industry with $42.88 billion...

https://www.pharmamanufacturing.com/articles/2011/095 A quiet but seismic shift is underway in global...

A quiet but revolutionary milestone may be unfolding in...

India’s pharmaceutical industry runs on the strength of its...

The Delhi High Court has restrained Dr. Reddy’s and...